Moderna stock surged Tuesday after the Centers for Disease Control and Prevention noted a two-week spike in positive Covid ...

Moderna leads vaccine rally amid rising respiratory infections, spurring investment in COVID-19, flu, and RSV solutions.

With COVID vaccine sales in the doldrums and a respiratory syncytial virus (RSV) vaccine market in “contraction”, Moderna CEO ...

The Covid-19 positivity rate has also seen a rise to 7.1% this past week, versus the 5.5% figure for the past four weeks.

Novavax (NVAX) and other vaccine developers rise as Investors react to rising flu and COVID-19 cases in the U.S. Read more here.

Moderna shares are trading higher by 3.1% Monday afternoon. The CDC reported a significant rise in acute respiratory ...

The intervening years have both sped and crawled by, too busy at times to take stock of all that has changed, too plodding to ...

Moderna stock was on track to see a weekly gain of 10% as of Wednesday following the first reported bird flu death in the US.

The Centers for Disease Control and Prevention is currently monitoring reports of a spike in human metapneumovirus (HMPV) in ...

With holiday gatherings and New Year's celebrations in the rearview mirror, many Americans are coming down with respiratory ...

Moderna led S&P 500 gainers Tuesday, a day after the first bird-flu death was reported in the U.S. The biotech company is developing a vaccine for H5N1.

COVID-19 has continued to claim lives at an average rate of about 900 deaths per week in the U.S. over the past year.